tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Oncolytics Biotech Bolsters Late-Stage Cancer Push With New Strategy and Biostatistics Leaders
PremiumCompany AnnouncementsOncolytics Biotech Bolsters Late-Stage Cancer Push With New Strategy and Biostatistics Leaders
23d ago
Oncolytics appoints John McAdory as EVP, strategy and operations
Premium
The Fly
Oncolytics appoints John McAdory as EVP, strategy and operations
23d ago
Advancing Pelareorep: Compelling Early Efficacy and High-Risk, High-Reward Valuation Support Buy Rating and $3 Target
Premium
Ratings
Advancing Pelareorep: Compelling Early Efficacy and High-Risk, High-Reward Valuation Support Buy Rating and $3 Target
24d ago
Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044
PremiumCompany AnnouncementsOncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044
29d ago
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials
Premium
Company Announcements
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials
1M ago
Promising Potential of Oncolytics Biotech’s Pelareorep in KRAS-Mutant MSS Colorectal Cancer Drives Buy Rating
Premium
Ratings
Promising Potential of Oncolytics Biotech’s Pelareorep in KRAS-Mutant MSS Colorectal Cancer Drives Buy Rating
2M ago
Oncolytics Biotech Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsOncolytics Biotech Reports Q3 2025 Financial Results
2M ago
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays
Premium
Company Announcements
Oncolytics Biotech Reschedules Shareholder Meeting Amid SEC Delays
3M ago
Positive Buy Rating for Oncolytics Biotech Following FDA Endorsement of Pelareorep Phase 3 Trial
Premium
Ratings
Positive Buy Rating for Oncolytics Biotech Following FDA Endorsement of Pelareorep Phase 3 Trial
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100